DEVA Holding Çerkezköy-I Manufacturing Facility has an enclosed area of 43,000 m2 established on an area of 52,000 m2 in the Çerkezköy Organized Industrial Zone, at a distance of approximately 110 km from Istanbul.

The facility is made up of modern buildings where liquids/semi-solids and solids, cephalosporin, penicillin, hormone products, inhaled products, sterile liquid ampoules and vials and soft gel capsules are manufactured.

While a total of 183 million units were manufactured in the manufacturing facility in 2022, 201.7 million units were manufactured in 2023.

The number of units manufactured in 2023 increased by 18.7 million units compared to 2022, which corresponds to an increase of 10%.

Liquids/Semi-Solids and Solids Manufacturing Unit

In the Liquids/Semi-Solids Manufacturing Unit, medicines in the form of syrup, drops and spray, cream and gel, suppositories and ovules are manufactured with state-of-the-art technology. In this unit, where a total of 37.5 million units of products were manufactured in 2022, a total of 40.9 million units, including 31.6 million units of syrups-drops and sprays and 9.3 million units of pomades, gels, suppositories and ovules, were manufactured in 2023. The quantity manufactured in the Liquids Manufacturing Unit in 2023 on a unit basis increased by 9% compared to 2022, with 3.4 million more units manufactured.

 

 

 

 

In the Solids Manufacturing Unit, medicines in the form of tablets/film tablets, capsules, and powders for suspension are manufactured with state-of-the-art technology. In this unit, where 65.9 million units of products were manufactured in 2022, a total of 72.8 million units of products were manufactured in 2023, including 69.2 million units of tablets/capsules and soft gel capsules, and 3.6 million units of suspensions. The quantity manufactured in the Solids Manufacturing Unit in 2023 on a unit basis increased by 10% compared to 2022, with 6.9 million more units manufactured.

 

Cephalosporin Manufacturing Unit (Beta-lactam I)

While 26.3 million units were manufactured in the Cephalosporin Manufacturing Unit in 2022, 22.8 million units of sterile powder vials for injection, 1.9 million units of oral suspension, 5 million units of film coated tablets and capsules, totaling 29.7 million units, were manufactured in 2023. The quantity manufactured in the Cephalosporin Manufacturing Unit in 2023 in terms of units increased by 13% compared to 2022, with 3.4 million more units manufactured.

 

 

Penicillin Manufacturing Unit (Beta-lactam II)

While 22.6 million units were manufactured in the Penicillin Manufacturing Unit in 2022, 7.1 million units of sterile powder vials for injection, 8.8 million units of oral suspension, 13.7 million units of film coated tablets, totaling 29.7 million units, were manufactured in 2023. The quantity manufactured in the Penicillin Manufacturing Unit in 2023 on a unit basis increased by 31% compared to 2022, with 7.1 million more units manufactured.

Hormone Products Manufacturing Unit

While 25.9 million units were manufactured in the Hormone Products Manufacturing Unit in 2022, 4.7 million units of cream/pomade, 4.6 million units of solid tablets and film tablets, and 15.2 million units of sterile ampoules, vials and drops, totaling 24.5 million units, were manufactured in 2023.

Inhaled Products Manufacturing Area

While 3.3 million units were manufactured in the Inhaled Products Manufacturing Unit in 2022, 2.6 million units were manufactured in 2023.

 

Sterile Liquid Ampoules, Vials and Soft Gel Capsules Manufacturing Unit

While 1.7 million units were manufactured in the Sterile Liquid Ampoules and Vials Manufacturing Unit in 2022, 1.5 million units were manufactured in 2023.